Association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial.
Rosa I. Gallagher(George Mason University), Emanuel Petricoin(George Mason University), Lamorna Brown Swigart(University of California, San Francisco), Julia Wulfkuhle(University of California, San Francisco), Christina Yau(Hospital Authority), Laura J. Esserman(University of California, San Francisco), Donald A. Berry(Berry & Associates (United States)), Denise M. Wolf, Gillian L. Hirst(University of California, San Francisco), Laura van ‘t Veer
Cited by 2
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k